News

Unexpected approach could crack key cancer signaling pathway

Cancer researchers have attempted to target the WNT pathway for decades without success due to severe toxicity issues. A new paper could solve that problem.
Written byAllison Whitten, PhD
| 2 min read
Glass-etched cryo-electron miscroscopy-based representation of the TNKS2 enzyme.

The researchers investigated inhibiting only the TNKS2 enzyme, shown here bound to the compound they tested, TDI-012804.

Credit: Dow lab

Register for free to listen to this article
Listen with Speechify
0:00
2:00

For decades, targeting the WNT signaling pathway in cancer has eluded drug developers. That’s because while it’s a crucial pathway that drives uncontrolled cell division and tumor growth, it’s also essential in maintaining homeostasis in normal healthy tissues. Thus, any therapeutic that targets WNT and harms cancer cells also harms healthy cells, leading to severe toxicity and intolerable side effects in preclinical models.

For example, a common strategy has been to target a pair of enzymes that regulate the WNT pathway, TNKS1 and TNKS2. But earlier work with dual inhibitors led to gastrointestinal damage in animal models.

Now, Lukas Dow’s lab at Weill Cornell Medicine may have found a surprising way around these harsh side effects. His lab first built genetic tools to silence TNKS1 and TNKS2 independently of each other rather than silencing both. “When we started using them in cancer cell lines we noticed something unexpected: In some cases, suppressing TNKS2 alone was sufficient to suppress WNT,” Dow told DDN.

In a new paper published in Nature Chemical Biology, Dow’s team generated a first-in-class TNKS2 inhibitor and showed that it successfully inhibited WNT signaling in TNKS1-deficient cell and organoid models.

Targeting cancer cells only

As part of the new work, Dow’s lab demonstrated that a genomic loss of TNKS1 sets up the cancer cells to be dependent upon TNKS2, which allows the TNKS2 selective inhibitor to shut down the WNT pathway — without affecting TNKS1-expressing healthy cells.

Continue reading below...
A 3D illustration of two sphericaA 3D illustration of two spherical cells in close contact, with glowing blue nuclei and additional out-of-focus cells in the background.l cells in close contact, with glowing blue nuclei and additional out-of-focus cells in the background.
Application NoteRevealing cell-cell interactions in immuno-oncology
Imaging-enabled flow cytometry helps distinguish biologically relevant cell-cell interactions from coincident events to support immunotherapy research.
Read More

The reason that some cancer cells naturally have a loss of TNKS1, Dow said, is because of a relatively common deletion on the short arm of chromosome 8, which houses the TNKS1 gene. These 8p deletions frequently happen in colorectal cancer — where targeting the WNT pathway is crucial, as WNT hyperactivation in the tumor is almost universal — as well as breast, lung, liver, prostate, and ovarian cancers. “In theory, the potential scope is quite broad, though the importance of WNT signaling as a target in these cancers is less well established,” said Dow.

Finding the TNKS2-selective small molecule drug was a challenge, however, because the active sites of TNKS1 and TNKS2 look nearly the same. “The key was a flexible loop in TNKS2 that behaves differently from the corresponding loop in TNKS1. Designing small molecules that exploit the conformational flexibility of the TNKS2 loop, ultimately led to our lead compound, TDI-012804,” said Dow.

Optimizing the compound

Dow’s team is hopeful they will eventually bring this new strategy to clinical trials for patients, but not with the current compound. He explained they plan to improve the drug-like properties while keeping the efficacy of TNKS2 inhibition in place. “The current lead compound is not optimized for in vivo testing, so clinical use is a long way in the future and would depend on successful development of modified compounds,” said Dow.

But finding a potential new way to target the WNT pathway without toxicity is already a step in the right direction for a target that the field has wanted to hit for many years. Current estimates suggest that the market for WNT inhibitors could reach $1.86 billion by 2032.

“The initial identification of a cancer-specific vulnerability hiding in plain sight was an exciting moment,” said Dow.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Allison Whitten

    Allison Whitten earned her PhD from Vanderbilt University in 2018 and continued her scientific training at Vanderbilt as a National Institute of Biomedical Imaging and Bioengineering (NIBIB) Postdoctoral Fellow. Her PhD and postdoctoral studies investigated the neurobiological causes of language impairments in neurological disorders. In 2020, she was awarded an AAAS Mass Media Fellowship to write for Discover Magazine. Her work has also appeared in WIRED, Quanta Magazine, Ars Technica, and more. 

    View Full Profile

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.